Natera (NTRA) Misses Q4 EPS by 17c, Offers Guidance

Natera (NASDAQ: NTRA) reported Q4 EPS of ($1.48), $0.17 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $173 million versus the consensus estimate of $168.55 million.

GUIDANCE:

Natera sees 2022 revenue of $770-790 million, versus the consensus of $763 million.

For earnings history and earnings-related data on Natera (NTRA) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Tenon Medical (TNON) Misses Q2 EPS by 395c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c